Swedbank AB Reduces Holdings in AbbVie Inc. $ABBV

Key Points

• Swedbank AB trimmed its stake in AbbVie by 0.6% in Q4, selling 10,981 shares and now holds 1,952,479 shares (about 0.11% of the company) valued at roughly $446.1 million.
• Q1 beat and raised guidance drove positive momentum—analysts have a consensus "Moderate Buy" on ABBV with an average price target of $252.90 and several firms raising price objectives.
• AbbVie declared a quarterly dividend of $1.73 (annualized $6.92, yield 3.4%), while insiders disclosed notable sales (e.g., EVP Perry Siatis sold 22,381 shares), signaling both income appeal and management selling activity.

Swedbank AB trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 0.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,952,479 shares of the company's stock after selling 10,981 shares during the period. Swedbank AB owned about 0.11% of AbbVie worth $446,122,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of AbbVie by 5.1% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,752,683 shares of the company's stock worth $860,528,000 after purchasing an additional 183,601 shares in the last quarter. Providence First Trust Co purchased a new position in shares of AbbVie during the 4th quarter worth approximately $708,000. AssuredPartners Investment Advisors LLC increased its stake in shares of AbbVie by 3.1% during the 4th quarter. AssuredPartners Investment Advisors LLC now owns 7,680 shares of the company's stock worth $1,755,000 after purchasing an additional 230 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in shares of AbbVie by 10.5% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 316,523 shares of the company's stock worth $72,322,000 after purchasing an additional 30,032 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of AbbVie during the 4th quarter worth approximately $183,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of recent research reports. Wall Street Zen cut shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 11th. Morgan Stanley raised their price objective on shares of AbbVie from $270.00 to $278.00 and gave the stock an "overweight" rating in a research note on Thursday, April 30th. Barclays started coverage on shares of AbbVie in a research note on Thursday, February 19th. They set an "overweight" rating and a $275.00 price objective for the company. Bank of America upgraded shares of AbbVie from a "neutral" rating to a "buy" rating and set a $234.00 target price on the stock in a research report on Thursday, April 30th. Finally, Guggenheim reiterated a "buy" rating and issued a $249.00 price target on shares of AbbVie in a report on Friday, May 1st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of "Moderate Buy" and an average price target of $252.90.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 beat and raised guidance spurred a rally: AbbVie reported stronger‑than‑expected Q1 results and lifted 2026 guidance, which pushed the stock higher in early May as investors reassessed growth prospects from Skyrizi, Rinvoq and the pipeline. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
• Positive Sentiment: Analyst and retail attention following the quarter: Coverage from Zacks highlights the company as a top‑searched/“trending” stock, reflecting elevated investor interest after the beat — attention that can amplify moves on earnings or guidance news. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
• Positive Sentiment: Dividend appeal remains strong: Multiple income‑focused outlets continue to list AbbVie as a high‑yield dividend candidate, supporting demand from dividend investors despite valuation considerations. Want to Collect a High Dividend Every Month? Invest in These 3 Stocks
• Neutral Sentiment: Positive clinical and real‑world data showcased at DDW: AbbVie presented long‑term and real‑world evidence for SKYRIZI (risankizumab) and RINVOQ (upadacitinib) in IBD, which supports the commercial outlook but will take time to materially change revenue trajectory. AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
• Neutral Sentiment: Industry tech/AI events mention AbbVie involvement: Participation in life‑science AI forums signals digital investment but is unlikely to move near‑term fundamentals. Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
• Negative Sentiment: Regulatory/manufacturing setback for a wrinkle treatment: The U.S. FDA declined to approve AbbVie’s wrinkle product over manufacturing concerns (reported April 23), a near‑term headwind that can pressure sentiment and highlight execution risk on noncore franchises. US FDA declines to approve AbbVie's wrinkle treatment due to manufacturing concerns (April 23)

Insiders Place Their Bets

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is owned by company insiders.

AbbVie Stock Down 1.0%

ABBV stock opened at $206.12 on Wednesday. AbbVie Inc. has a 52-week low of $176.57 and a 52-week high of $244.81. The stock's fifty day simple moving average is $214.17 and its 200-day simple moving average is $221.34. The stock has a market capitalization of $364.46 billion, a price-to-earnings ratio of 101.54, a price-to-earnings-growth ratio of 0.72 and a beta of 0.32.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The business had revenue of $15 billion for the quarter, compared to analysts' expectations of $14.72 billion. During the same quarter last year, the firm earned $2.46 earnings per share. The business's revenue was up 12.4% on a year-over-year basis. As a group, analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date is Wednesday, April 15th. AbbVie's dividend payout ratio (DPR) is 340.89%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.